Inflammatory bowel disease consists of ulcerative colitis and Crohn's disease.
Ulcerative colitis is a diffuse mucosal inflammation limited to the colon while Crohn's disease is a patchy, transmural inflammation that occurs in any part of the gastrointestinal tract.
The ileum and colon are the most frequently affected sites.
Treatment with the anti-β7 integrin monoclonal antibody etrolizumab led to a significant reduction in serum levels of soluble (s) MAdCAM-1*, which mediates lymphocyte trafficking to the gastrointestinal lining — thus shedding light on the mechanism behind the action of etrolizumab in patients with Crohn’s disease, according to a study presented at the Crohn’s and Colitis Congress (CCC) 2019.
Women with inflammatory bowel disease (IBD), particularly Crohn’s disease, are at high risk of developing mental illness such as mood, anxiety and substance use disorders during the postpartum period, a study suggests.
The monoclonal antibody vedolizumab is more likely to induce complete response in Crohn’s disease (CD) patients with early disease than in their peers with longer disease duration, a study has shown. On the other hand, this pattern of response is not seen in patients with ulcerative colitis.
The favourable safety profile of vedolizumab in patients with inflammatory bowel disease (IBD) persists even in real-world clinical practice, according to the first 4 years of post-marketing safety data reported at AIBD 2018.
Patients with obesity have an elevated risk of intra- and postoperative complications following surgical treatment for inflammatory bowel disease (IBD), according to a presentation at the recent Advances in Inflammatory Bowel Disease meeting (AIBD 2018).
The α4β7 integrin antibody vedolizumab continues to show efficacy and safety in patients with inflammatory bowel disease (IBD) in an era beyond tumour necrosis factor (TNF) inhibitors, according to a presentation at the annual Advances in Inflammatory Bowel Diseases (AIBD) 2018 meeting.
Among patients with inflammatory bowel disease (IBD), older age at the time of IBD diagnosis and longer disease duration are associated with a heightened risk of developing colitis-associated neoplasia, a study has found.
The biosimilar CT-P13 shows equivalent effectiveness to its reference product infliximab in patients with Crohn’s disease (CD) who are infliximab-naïve, with no differences in safety outcomes, a real-world equivalence study finds.
The Mandarin-speaking population in Singapore (SG) has deemed the translated Chronic Liver Disease Questionnaire (CLDQ) culturally acceptable, with only two items that needed revision in the finalized CLDQ-SG, according to a recent study.
Understanding the factors which induce visceral hypersensitivity (VH) in patients with functional gastrointestinal disorders (FGIDs) may help doctors manage patients and develop new treatments, says an expert.
Administration of a probiotic appears to be a safe and effective therapeutic alternative for minimal hepatic encephalopathy (MHE) in patients with liver cirrhosis, according to a Greek study presented at the 26th Conference of the Asian Pacific Association for the Study of the Liver (APASL) held in Shanghai, China.